Previously, it was reported that kidney microRNA-21 (miR-21) expression is significantly increased in <i>Col4α3</i><sup>-/-</sup> mice, and administration of anti-miR-21 oligonucleotides (anti-miR-21) attenuates kidney disease progression in <i>Col4α3</i><sup>-/-</sup> mice, indicating that miR-21 is a viable therapeutic target for Alport syndrome.